• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Big Sky Biomedical Appoints Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director

    3/7/22 12:00:00 PM ET
    $CSII
    $MDT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CSII alert in real time by email

    MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director.

    "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I look forward to addressing significant underserved patient populations and large unmet clinical needs through compelling and differentiated technologies."

    Dr. Egeland received his medical degree from Harvard Medical School and was a Rhodes Scholar at the University of Oxford, where he completed his Ph.D. and M.B.A. Previously, he served as the Head of Strategic Ventures and Chief Medical Officer for Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII). Prior to his tenure at CSI, Ryan led teams in Business Development & Licensing, Medical & Scientific Affairs, and Product Marketing at Medtronic (NYSE:MDT), Covidien, and ev3. Before this, he trained as a plastic and reconstructive surgeon at Northwestern Memorial Hospital and has practiced in both large academic hospital and office-based lab settings.

    "We are exceedingly pleased to welcome Ryan in a managing role at Big Sky Biomedical," stated JC Sun, Founding Partner of the incubator. "Ryan brings extensive, cross-functional expertise to our nimble, capital-efficient companies. With his guidance and operational involvement, not only am I very confident in our ability to execute in the near term, but am extremely bullish about Big Sky's potential to streamline zero to one value creation, setting a new standard for accelerating next-level medical device design and development."

    About Big Sky Biomedical, LLC

    Founded by a group of medical device serial entrepreneurs with extensive expertise in the cardiovascular space, Big Sky Biomedical is a highly specialized incubator focused on rapid, capital-efficient therapy development. To learn more about Big Sky Biomedical, please visit https://bigskybiomedical.com.

    Media Contact

    Media Relations

    [email protected]

    (763) 228-8573

    Media Contact

    Media Relations, Big Sky Biomedical, +1 (763) 228-8573, [email protected]

     

    SOURCE Big Sky Biomedical

    Get the next $CSII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSII
    $MDT

    CompanyDatePrice TargetRatingAnalyst
    Medtronic plc.
    $MDT
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    Medtronic plc.
    $MDT
    6/16/2025$110.00Outperform
    Leerink Partners
    Medtronic plc.
    $MDT
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    Medtronic plc.
    $MDT
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    Medtronic plc.
    $MDT
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    Medtronic plc.
    $MDT
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    Medtronic plc.
    $MDT
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    Medtronic plc.
    $MDT
    5/30/2024$83.00Sell
    Goldman
    More analyst ratings

    $CSII
    $MDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & President Cardiovascular Kiil Harry Skip sold $788,048 worth of Ordinary Shares (8,605 units at $91.58), decreasing direct ownership by 19% to 35,615 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    9/5/25 4:18:13 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,052 units of Ordinary Shares, decreasing direct ownership by 2% to 51,939 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/21/25 4:22:11 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CSII
    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions

    TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for people with Parkinson's – has been recognized by TIME on its annual list of Best Inventions. There are over 10 million people living with Parkinson's disease globally,1 and while there is currently no cure, Medtronic deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. Medtronic recently enhanced its Percept™ DBS

    10/9/25 10:10:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

    Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annuallyAVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients NEW HOPE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Orches

    10/9/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Medtronic initiates U.S. IDE clinical study evaluating Hugo™ robotic-assisted surgery system for gynecological procedures

    First procedures completed and enrollment underway in Embrace Gynecology study, furthering the company's progress to expand minimally invasive treatment options to patients in the United States GALWAY, Ireland, Oct. 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo™ robotic-assisted surgery (RAS) system in robotic-assisted gynecological procedures. The first procedures, total hysterectomies, were successfully completed at AHN West Penn Hospital in Pittsburgh, PA, by Dr. Sarah Crafton and Dr. Eirwen Miller, Embrace Gynecology study

    10/8/25 7:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Wolfe Research

    Wolfe Research upgraded Medtronic from Underperform to Peer Perform

    6/30/25 7:56:30 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Leerink Partners initiated coverage on Medtronic with a new price target

    Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00

    6/16/25 7:51:25 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Citigroup with a new price target

    Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously

    3/4/25 7:37:34 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MDT
    SEC Filings

    View All

    SEC Form 25-NSE filed by Medtronic plc.

    25-NSE - Medtronic plc (0001613103) (Subject)

    9/29/25 10:44:27 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form CERT filed by Medtronic plc.

    CERT - Medtronic plc (0001613103) (Filer)

    9/29/25 9:53:17 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Medtronic plc.

    8-K - Medtronic plc (0001613103) (Filer)

    9/29/25 8:45:28 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $CSII
    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

    SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

    2/13/24 3:24:48 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/12/24 1:59:55 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CSII
    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic reports first quarter fiscal 2026 financial results

    11th quarter in a row of mid-single digit organic revenue growth;Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organicGAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2%Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidanceCardiac Ablation Solutions revenue increased nearly 50%, incl

    8/19/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for second quarter of fiscal year 2026

    GALWAY, Ireland, Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc,

    8/14/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for fourth quarter of fiscal year 2025

    GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

    3/6/25 4:30:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care